{
  "abstract": "Background/Objectives Eptinezumab is a relatively new prophylactic medication for chronic migraine prevention. It was only introduced onto the Pharmaceutical Benefits Scheme in Australia in August 2023, so there is limited real-world data regarding its safety, tolerability and efficacy. Methods Single centre retrospective audit of patients receiving eptinezumab for chronic migraine prevention between 1st September 2023 and 31st December 2024. Headache characteristics were compared at baseline and three months after eptinezumab administration. Primary outcomes were mean reductions in monthly headache days (MHD) and monthly migraine days (MMD). Secondary outcomes were mean monthly reductions in acute abortive medications, and adverse events. Results Of the 60 patients who received eptinezumab during the study period, 80% (48/60) were female with mean age 42.53 years (SD 12.17). Three months after eptinezumab infusion, MMD reduced from 22.63 days to 15.17 days (p value <0.001), and MHD reduced from 26.02 days to 19.02 days (p value <0.001). Acute analgesic use decreased from 16.25 days to 11.5 days (p value<0.001). The vast majority (95%, 57/60) had no immediate adverse events. Of 25 patients with 6-months post infusion data, mean MMD and MHD decreased to 7.84 days (p<0.001) and 13.42 days (p<0.001) respectively. Statistically significant reductions to both co-primary outcomes were achieved in those with pre-existing medication-overuse headache and those who had previously failed onabotulinumtoxinA, fremenezumab and galcanezumab. Conclusion Our findings show that eptinezumab is a safe, well-tolerated migraine prophylactic that decreases monthly migraine and headache days in resistant chronic migraine.",
  "authors": [
    {
      "affiliations": [
        "Alfred Health, Melbourne, VIC, Australia",
        "Monash University, Melbourne, VIC, Australia"
      ],
      "name": "Lakshini Gunasekera"
    },
    {
      "affiliations": [
        "Alfred Health, Melbourne, VIC, Australia",
        "Monash University, Melbourne, VIC, Australia"
      ],
      "name": "Shuli Cheng"
    },
    {
      "affiliations": [
        "Alfred Health, Melbourne, VIC, Australia",
        "Monash University, Melbourne, VIC, Australia"
      ],
      "name": "Emma Foster"
    },
    {
      "affiliations": [
        "Alfred Health, Melbourne, VIC, Australia",
        "Monash University, Melbourne, VIC, Australia"
      ],
      "name": "Shobi Sivathamboo"
    },
    {
      "affiliations": [
        "Alfred Health, Melbourne, VIC, Australia",
        "Monash University, Melbourne, VIC, Australia"
      ],
      "name": "Terence O’Brien"
    },
    {
      "affiliations": [
        "Alfred Health, Melbourne, VIC, Australia",
        "Monash University, Melbourne, VIC, Australia"
      ],
      "name": "Helmut Butzkueven"
    },
    {
      "affiliations": [
        "Alfred Health, Melbourne, VIC, Australia",
        "Monash University, Melbourne, VIC, Australia",
        "HER Centre, Melbourne, VIC, Australia"
      ],
      "name": "Jayashri Kulkarni"
    },
    {
      "affiliations": [
        "Alfred Health, Melbourne, VIC, Australia",
        "Monash University, Melbourne, VIC, Australia"
      ],
      "name": "Elspeth Hutton"
    }
  ],
  "title": "CS6 Retrospective audit of the real-world safety and efficacy profile of eptinezumab for resistant chronic migraine",
  "uid": "8ad09b12-9855-52e8-ac35-006f2cecb81d"
}